Abhijeet Kamasamudram

Abhijeet Kamasamudram is a seasoned finance executive and Chartered Accountant with over 25 years of experience in corporate finance, financial planning, and operations across pharmaceutical, food & beverage, and venture capital sectors. He is currently serving as CFO and Whole Time Director at Synthimed Labs, a pharmaceutical company that is part of the IndiaRF portfolio, a joint venture between Bain Capital and the Piramal Group.

Kamasamudram's career spans multiple multinational corporations and industries. He began his professional journey in 2004 as Financial Planning and Analysis Manager at GE Asset Intelligence in Chicago, United States, where he developed expertise in financial modeling and corporate analytics. He later returned to India to take on progressively senior finance roles in the pharmaceutical sector, serving as Financial Controller for India & Sri Lanka at AstraZeneca in 2008, followed by a position as Finance Director at Abbott in 2011.

In 2014, Kamasamudram transitioned into the venture capital and private equity ecosystem, joining Helion Venture Partners as Director of Finance. Helion Venture Partners is one of India's prominent early-stage venture capital firms, and this role exposed him to startup financing, portfolio company operations, and investment fund management. His experience at Helion likely informed his understanding of early-stage investing and startup ecosystems.

More recently, Kamasamudram has held board and executive roles at McCain Foods India Private Limited, where he serves as Wholetime Director - Finance & Supply Chain and board member. McCain Foods is a global leader in frozen food products, and his role involves strategic oversight of finance operations and supply chain management for the Indian subsidiary. He also served as a director of Synthimed Labs Private Limited, a pharmaceutical company incorporated in July 2023 in Chandigarh, though he is no longer in that position. Synthimed Labs operates in drug formulation and development within the pharma sector.

Kamasamudram holds a Chartered Accountant qualification from The Institute of Chartered Accountants of India (ICAI), one of the most rigorous professional accounting credentials in India. He is based in Delhi and maintains over 500 professional connections on LinkedIn.

Limited Public Investment Information: Based on available public data, Abhijeet Kamasamudram is classified as an angel investor focused on Seed Round investments. However, there is minimal publicly available information about his specific investment thesis, portfolio companies, or active angel investing activities.

His professional background suggests potential interest in:

It is possible that Kamasamudram engages in angel investing on a selective, relationship-based basis rather than as a prolific public investor, which would explain the limited visibility of his investment portfolio.

• Healthcare and pharmaceutical sectors (based on extensive experience at AstraZeneca, Abbott, and Synthimed Labs)
• Early-stage companies (informed by his role at Helion Venture Partners)
• Companies requiring financial structuring and operational expertise

No publicly documented portfolio companies as of March 2026.

The research did not uncover publicly available information about specific startups or companies in which Abhijeet Kamasamudram has made angel investments. His investment activities may be conducted privately or through informal networks not tracked by major databases like Crunchbase, AngelList, CB Insights, or PitchBook.

• Board Member: McCain Foods India Private Limited (Wholetime Director - Finance & Supply Chain)
• Former Director: Synthimed Labs Private Limited
• Former Finance Director: Helion Venture Partners
• Professional Credential: Chartered Accountant, Institute of Chartered Accountants of India (ICAI)

Limited public information available as of March 2026. Abhijeet Kamasamudram maintains a relatively low public profile as an angel investor. While he is listed as an angel investor focused on seed-stage investments, publicly available databases and news sources do not document specific portfolio companies, investment amounts, or detailed investment activities. His primary public presence is through his corporate finance and executive roles rather than as an active angel investor with a substantial public portfolio.

The lack of publicly documented investments does not necessarily indicate a lack of investing activity—many angel investors operate through private networks, family offices, or informal syndicates that are not widely reported. Additionally, Indian angel investing activity is not always comprehensively tracked in Western databases.